

Douglas R Adkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8716444/publications.pdf>

Version: 2024-02-01

91
papers

3,814
citations

257450

24
h-index

128289

60
g-index

91
all docs

91
docs citations

91
times ranked

4919
citing authors

#	ARTICLE	IF	CITATIONS
1	T cell subtype profiling measures exhaustion and predicts anti-PD-1 response. <i>Scientific Reports</i> , 2022, 12, 1342.	3.3	7
2	Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer. <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 108-115.	0.5	2
3	Integrative genomic analysis reveals low T-cell infiltration as the primary feature of tobacco use in HPV-positive oropharyngeal cancer. <i>IScience</i> , 2022, 25, 104216.	4.1	6
4	Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. <i>Clinical Cancer Research</i> , 2022, 28, 903-914.	7.0	14
5	Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 2355.	3.7	6
6	Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84).. <i>Journal of Clinical Oncology</i> , 2022, 40, e18033-e18033.	1.6	0
7	Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2517-2517.	1.6	3
8	Phase 2, randomized, double-blind trial of EC-18 versus placebo to mitigate the development and time course of oral mucositis from concomitant chemoradiation for head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12106-12106.	1.6	1
9	A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with PIK3CA-mutated/amplified and/or HRAS-overexpressing recurrent/metastatic head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS6104-TPS6104.	1.6	0
10	Pralsetinib in patients (pts) with advanced or metastatic <i>RET</i>-altered thyroid cancer (TC): Updated data from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6080-6080.	1.6	5
11	TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS6099-TPS6099.	1.6	0
12	Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 2326-2339.	7.0	16
13	nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. <i>Medical Oncology</i> , 2021, 38, 35.	2.5	11
14	Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. <i>Oral Oncology</i> , 2021, 114, 105164.	1.5	11
15	Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105173.	1.5	15
16	Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105192.	1.5	22
17	Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 6008-6008.	1.6	19
18	The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with <i>HRAS</i> mutations.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6087-TPS6087.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Abstract CT153: Correlation of <i>CDKN2A</i> genomic alterations with tumor response to palbociclib given before chemoradiation therapy to patients with human papillomavirus-unrelated, locally advanced head and neck squamous-cell carcinoma. <i>Cancer Research</i> , 2021, 81, CT153-CT153.	0.9	1
20	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 491-501.	11.4	192
21	438...A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. , 2021, 9, A468-A468.		2
22	358...Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: a phase 1-2 trial. , 2021, 9, A385-A385.		0
23	Extranodal extension is a strong prognosticator in HPV-positive oropharyngeal squamous cell carcinoma. <i>Laryngoscope</i> , 2020, 130, 939-945.	2.0	56
24	Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer. <i>Medical Oncology</i> , 2020, 37, 12.	2.5	5
25	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Related Head and Neck Cancer: A Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5140-5152.	7.0	163
26	A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. <i>Cancer</i> , 2020, 126, 3237-3243.	4.1	12
27	Duration of radiation therapy is associated with worse survival in head and neck cancer. <i>Oral Oncology</i> , 2020, 108, 104819.	1.5	14
28	354...A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer. , 2020, , .		1
29	Patterns of care and survival outcomes for laryngeal small cell cancer. <i>Head and Neck</i> , 2019, 41, 722-729.	2.0	2
30	Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 1295-1305.	10.7	87
31	nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 93.	2.5	4
32	Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 134, 81-88.	0.6	24
33	Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 867.	6.3	29
34	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , 2019, 393, 156-167.	18.7	1,153
35	Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6013-6013.	1.6	14
36	Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6018-6018.	1.6	34

#	ARTICLE	IF	CITATIONS
37	Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.. Journal of Clinical Oncology, 2019, 37, 6020-6020.	1.6	19
38	CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2019, 37, 6025-6025.	1.6	5
39	An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.. Journal of Clinical Oncology, 2019, 37, 6033-6033.	1.6	13
40	KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2019, 37, TPS6090-TPS6090.	1.6	19
41	Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 427-435.	0.8	63
42	Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers. Oral Oncology, 2018, 86, 1-7.	1.5	27
43	Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer. Clinical and Translational Radiation Oncology, 2018, 13, 1-6.	1.7	1
44	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck. JAMA Oncology, 2018, 4, 1583.	7.1	84
45	Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging. Head and Neck, 2018, 40, 2280-2287.	2.0	14
46	Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care. Cancer Medicine, 2018, 7, 3592-3603.	2.8	18
47	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Lancet Oncology, The, 2018, 19, 1082-1093.	10.7	21
48	Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity. Cell Reports, 2018, 24, 2167-2178.	6.4	26
49	A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2018, 36, TPS6091-TPS6091.	1.6	1
50	Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. Medical Oncology, 2017, 34, 28.	2.5	9
51	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2017, 11, 338-345.	2.6	9
52	Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral Oncology, 2017, 73, 65-69.	1.5	40
53	Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil. Cancer, 2017, 123, 4594-4607.	4.1	46
54	nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral Oncology, 2017, 72, 26-31.	1.5	12

#	ARTICLE	IF	CITATIONS
55	Reevaluation of postoperative radiation dose in the management of human papillomavirus-positive oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1643-1649.	2.0	18
56	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 58, 41-48.	1.5	78
57	nab -Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 61, 1-7.	1.5	18
58	PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2016, 61, 31-40.	1.5	23
59	Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. <i>BMC Cancer</i> , 2016, 16, 19.	2.6	10
60	PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, E1756-61.	2.0	20
61	High E6 Gene Expression Predicts for Distant Metastasis and Poor Survival in Patients With HPV-Positive Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1132-1141.	0.8	25
62	A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2575-2575.	1.6	16
63	Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2015, 4, 481-489.	2.8	18
64	Looking beyond the CRT paradigm: Why induction chemotherapy is worthy of pursuit. <i>Oral Oncology</i> , 2015, 51, 103-104.	1.5	2
65	Outcomes of P16 positive oropharyngeal squamous cell carcinoma treated with surgery and adjuvant IMRT. <i>Journal of Radiation Oncology</i> , 2015, 4, 37-46.	0.7	0
66	Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patients. <i>Radiation Oncology</i> , 2015, 10, 8.	2.7	6
67	RTOG 0522: Huge Investment in Patients and Resources and No Benefit With Addition of Cetuximab to Radiotherapy-Why Did This Occur?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1223-1224.	1.6	6
68	The role of cetuximab in induction chemotherapy: Comparison of APF-C (nab-paclitaxel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 23 locally advanced head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6042-6042.	1.6	1
69	A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6043-6043.	1.6	3
70	A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6060-6060.	1.6	19
71	A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2621-TPS2621.	1.6	2
72	Prospective study of a tailored comprehensive cancer gene (TCCG) set built on a next generation sequencing (NGS) platform in incurable head and neck squamous cell carcinoma (The Pro-TCCG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5		

#	ARTICLE	IF	CITATIONS
73	A phase I trial of pazopanib (suspension formulation) added to a fixed dose of cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2015, 33, e17028-e17028.	1.6	0
74	Correlation of Ki-67 expression and tumor response to induction chemotherapy (IC) containing cell cycle-specific agents in patients (pts) with head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2015, 33, e17077-e17077.	1.6	0
75	Correlation of SPARC expression and primary tumor site response(PTSR) and relapse to nab-paclitaxel vs docetaxel-based induction chemotherapy (IC) in patients(Pts) with HNSCC.. Journal of Clinical Oncology, 2015, 33, e17079-e17079.	1.6	0
76	Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma. Ecancermedicalsecience, 2014, 8, 480.	1.1	11
77	A prospective trial comparing FDG PET / CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. Cancer Medicine, 2014, 3, 1493-1501.	2.8	13
78	Response to: Pre-mediations for cetuximab induced infusion reactions-Commentary™. Oral Oncology, 2014, 50, e72.	1.5	0
79	Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget, 2014, 5, 9281-9294.	1.8	27
80	Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma. Journal of Radiation Oncology, 2013, 2, 27-34.	0.7	30
81	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 257-264.	10.7	617
82	A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer, 2013, 119, 766-773.	4.1	31
83	Antiangiogenic Agents for Nonmalignant Brain Tumors. Journal of Neurological Surgery, Part B: Skull Base, 2013, 74, 136-141.	0.8	30
84	The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).. Journal of Clinical Oncology, 2012, 30, 5501-5501.	1.6	30
85	Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?. Current Opinion in Hematology, 2008, 15, 555-560.	2.5	34
86	A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2005, 106, 1800-1800.	1.4	0
87	Once Daily Ganciclovir (ODG) as Initial Pre-Emptive Therapy (PT) Delayed until Threshold Viral Load $\leq 10,000$ Copies/ml: A Safe and Effective Strategy for Post-Allogeneic Stem Cell Transplant (ASCT) Patients.. Blood, 2004, 104, 3158-3158.	1.4	0
88	Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood, 2001, 98, 266-271.	1.4	233
89	Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood, 2000, 95, 3605-3612.	1.4	69
90	Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts. Transfusion, 1997, 37, 737-748.	1.6	63

#	ARTICLE	IF	CITATIONS
91	Risk Factors for Functional Outcomes in Advanced Laryngeal Squamous Cell Carcinoma. Laryngoscope, 0, , .	2.0	0